FRA:CVS • US1266501006
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CVS HEALTH CORP (CVS.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-06-22 | Deutsche Bank | Maintains | Buy |
| 2021-05-19 | BMO Capital | Maintains | Market Perform |
| 2021-05-19 | Wolfe Research | Maintains | Outperform |
| 2021-05-19 | Barclays | Maintains | Overweight |
| 2021-05-19 | Wells Fargo | Initiate | Equal-Weight |
| 2021-05-12 | Mizuho | Maintains | Buy |
| 2021-05-06 | BMO Capital | Maintains | Market Perform |
| 2021-05-06 | Credit Suisse | Maintains | Outperform |
| 2021-05-05 | Raymond James | Maintains | Strong Buy |
| 2021-04-14 | Truist Securities | Maintains | Buy |
| 2021-04-14 | Morgan Stanley | Maintains | Overweight |
| 2021-03-17 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 357.776B 10.95% | 372.809B 4.20% | 402.067B 7.85% | 409.426B 1.83% | 427.588B 4.44% | 447.269B 4.60% | 473.107B 5.78% | 493.393B 4.29% | 514.995B 4.38% | 547.437B 6.30% | 581.527B 6.23% | |
| EBITDA YoY % growth | N/A 0.50% | N/A -27.63% | N/A 15.92% | 18.005B 5.29% | 19.98B 10.97% | 22.141B 10.82% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 15.086B -7.39% | 10.038B -33.46% | 10.502B 4.62% | 15.405B 46.69% | 17.152B 11.34% | 19.105B 11.39% | 21.079B 10.33% | 22.701B 7.69% | N/A | N/A | N/A | |
| Operating Margin | 4.22% | 2.69% | 2.61% | 3.76% | 4.01% | 4.27% | 4.46% | 4.60% | N/A | N/A | N/A | |
| EPS YoY % growth | 8.74 0.46% | 5.42 -37.99% | 6.75 24.54% | 7.25 7.45% | 8.27 14.02% | 9.60 16.14% | 10.39 8.16% | 11.31 8.91% | 12.30 8.73% | 13.61 10.67% | 15.18 11.50% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.26 0.30% | 1.85 1.95% | 1.81 12.83% | 1.33 22.41% | 2.53 11.90% | 2.11 14.14% | 2.04 12.80% | 1.65 23.31% | 2.92 15.82% | 2.51 19.19% | 2.36 15.85% | 1.84 12.00% |
| Revenue Q2Q % growth | 95.989B 1.48% | 100.437B 1.54% | 104.309B 1.40% | 107.349B 1.57% | 100.969B 5.19% | 106.044B 5.58% | 110.257B 5.70% | 113.51B 5.74% | 106.42B 5.40% | 111.934B 5.55% | 116.827B 5.96% | 120.668B 6.31% |
| EBITDA Q2Q % growth | 5.163B 19.27% | 4.532B 16.53% | 4.547B 19.00% | 3.47B 10.93% | 5.671B 9.84% | 5.037B 11.14% | 4.86B 6.88% | 4.155B 19.74% | 6.442B 13.60% | 5.663B 12.43% | 6.011B 23.68% | 4.208B 1.28% |
| EBIT Q2Q % growth | 4.62B 36.93% | 3.935B 65.27% | 3.916B 55.52% | 2.958B 40.06% | 5.069B 9.72% | 4.347B 10.47% | 4.23B 8.02% | 3.449B 16.60% | 5.711B 12.67% | 4.955B 13.99% | 4.866B 15.04% | 3.793B 9.97% |
All data in USD
33 analysts have analysed CVS.DE and the average price target is 81.34 EUR. This implies a price increase of 20.47% is expected in the next year compared to the current price of 67.52.
CVS HEALTH CORP (CVS.DE) will report earnings on 2026-04-29, before the market open.
The consensus EPS estimate for the next earnings of CVS HEALTH CORP (CVS.DE) is 2.26 EUR and the consensus revenue estimate is 95.99B EUR.
The number of analysts covering CVS HEALTH CORP (CVS.DE) is 33.